Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Libertas Academica
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411522/ |